Abstract 620P
Background
Cancer constitutes a major burden to global health and the critical role of early diagnosis for cancer management is self-evident. Even though various miRNA-based signatures have been developed, their clinical utilization is limited due to various reasons. In this article, we innovatively developed a signature based on pairwise expression of miRNAs (miRPs) for pan-cancer diagnosis using machine learning approach.
Methods
miRNA spectrum of 15832 patients with 13 different cancers from 10 cohorts were analyzed. 15148 patients were divided into training, validation, and test sets with a ratio of 7:2:1, while 648 patients were utilized as external test. Pairwise comparison was performed to generate miRP score, defined by the comparison between two miRNAs, in training set. Five different machine-learning (ML) algorithms (XGBoost, SVM, RandomForest, LASSO, and Logistic) were adopted for signature construction. The best ML algorithm and the optimal number of miRPs included were identified using AUC and youden index in validation. Performance of the ideal model was evaluated in test and external set based on AUC, Youden index, positive predictive value (PPV), negative predictive value (NPV), sensitivity, specificity, and accuracy. The AUC of entire cohorts was compared to previously published 25 signatures.
Results
The Random Forest approach including 31 miRPs (31-miRP) outperformed others and was retained for further evaluation. The AUC of 31-miRP ranges 0.980-1.000 in different set. Remarkably, 31-miRP exhibited advantages in differentiating different cancers from normal tissues. Moreover, 31-miRP demonstrate superiorities in detecting early-stage cancers, with AUC ranging from 0.961-0.998. Compared to previously published 25 different signatures, 31-miRP also demonstrated clear advantages. Remarkably, 31-miRP also exhibited promising capabilities in differentiating cancers from corresponding benign lesions.
Conclusions
The 31-miRP exhibited outstanding diagnostic performance, characterized by high accuracy and sensitivity, thereby holding potential as a reliable tool for cancer diagnosis at early stage. Nevertheless, its effectiveness still warrants further investigation in real-world setting in future.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
CAMS Innovation Fund for Medical Sciences (No.2021-I2M-1-050); National Natural Science Foundation for Young Scientists of China (No. 82203025).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
87TiP - Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
Presenter: Mustafa Syed
Session: Poster Display
Resources:
Abstract
88TiP - A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
Presenter: Nick Pavlakis
Session: Poster Display
Resources:
Abstract
93P - Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Presenter: Daisuke Kotani
Session: Poster Display
Resources:
Abstract
94P - Sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer in the nationwide cancer genome screening project in Japan (SCRUM-Japan GI-SCREEN)
Presenter: Takeshi Kajiwara
Session: Poster Display
Resources:
Abstract
95P - Interim results of a prospective randomized controlled study to compare the clinical outcomes of total neoadjuvant therapy vs long course chemoradiotherapy in locally advanced carcinoma rectum
Presenter: Sandip Barik
Session: Poster Display
Resources:
Abstract
96P - Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study
Presenter: Jingdong Zhang
Session: Poster Display
Resources:
Abstract
97P - Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
Presenter: Rui-Hua Xu
Session: Poster Display
Resources:
Abstract
98P - Real clinical impact of postoperative surgical complications after colon cancer surgery
Presenter: Toru Aoyama
Session: Poster Display
Resources:
Abstract
99P - Extended lymphadenectomy may not be necessary for MSI-H colon cancer patients after immunotherapy
Presenter: Rongxin Zhang
Session: Poster Display
Resources:
Abstract
100P - Identification of phenomic data in the pathogenesis of colorectal cancer: A UK biobank data analysis
Presenter: Shirin Hui Tan
Session: Poster Display
Resources:
Abstract